Use of antibacterial agents in renal failure

Infectious Disease Clinics of North America

Volumn 18, Issue 3, 2004, Pages 551-579

  Livornese Jr , Lawrence L ^a,b   Slavin, Dorothy ^b,c   Gilbert, Brett ^b   Robbins, Paul ^b   Santoro, Jerome ^b,c  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b LANKENAU HOSPITAL   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFAZOLIN; CEFDINIR; CEFDITOREN; CEFEPIME; CEFIXIME; CEFOPERAZONE; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFPODOXIME; CEFPROZIL; CEFTAZIDIME; CEFTIBUTEN; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; GENTAMICIN; NETILMICIN; STREPTOMYCIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ACHILLES TENDON RUPTURE; ACUTE KIDNEY FAILURE; AUDITORY HALLUCINATION; BACTERIAL INFECTION; BLOOD CLOTTING DISORDER; CREATININE CLEARANCE; DIALYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG MONITORING; HEMODIALYSIS; HEMOFILTRATION; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER NECROSIS; LIVER TOXICITY; MAINTENANCE DRUG DOSE; MYOCLONUS; NEPHROTOXICITY; NEUROLOGICAL COMPLICATION; OTOTOXICITY; PERITONEAL DIALYSIS; PSYCHOSIS; REVIEW; SEIZURE; SIDE EFFECT; THROMBOCYTE DYSFUNCTION; UREMIA; VISUAL HALLUCINATION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DIALYSIS; DRUG MONITORING; HUMANS; KIDNEY FAILURE;

EID: 4043083521     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2004.04.013     Document Type: Review

References (66)

1. Aronoff G.R., Abel S.R. Principles of administering drugs to patients with renal failure. Brenner B.M., Stein J.H. Contemporary issues in nephrology. 1986;77-82 Churchill-Livingstone, New York
2. Hurwitz A. Antacid therapy in drug kinetics. Clin Pharmacokinet. 12:1977;269-280
3. Bennett W., Arnoff G., Golper T., et al. Drug prescribing in renal failure, dosing guidelines for adults. 1994;American College of Physicians, Philadelphia
4. Reindenberg M.M. The biotransformation of drugs in renal failure. Am J Med. 62:1977;482-485
5. Cockroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16:1976;31-41
6. Pesola G.R., Akhavan I., Madu A., Shah N.K., Carlton G.C. Prediction equation estimates of creatinine clearance in the intensive care unit. Intensive Care Med. 19:1993;39-43
7. Devine B.J. Gentamicin pharmacokinetics. Drug Intell Clin Pharm. 8:1974;650-655
8. Sher P.P. Drug interferences with clinical laboratory tests. Drugs. 24:1982;24
9. Sandburg T., Trollfors B. Effect of trimethoprim on serum creatinine in patients with acute cystitis. J Antimicrob Chemother. 17:1986;123
10. Harrington D., Drusano G., Smalls V., et al. False elevations of serum creatinine. JAMA. 252:1984;2962
11. Sherman R.A., Eisenger R.P., Weinstein M.P., et al. Cefoxitin-induced pseudo acute renal failure. Clin Ther. 4:1981;114
12. Demczar D.J., Nafziger A.N., Bertino J.S. Pharmacokinetics of gentamicin at traditional versus high doses: implications for once daily aminoglycoside dosing. Antimicrob Agents Chemother. 41:1997;1115-1119
13. Lacy M.K., Nicolau D.P., Nightingale C.H., Quintilaini R. The pharmacodynamics of aminoglycosides. Clin Infect Dis. 27:1998;23-27
14. Chuck S.K., Raber S.R., Rodvold K.A., Areft D. National survey of extended-interval aminoglycoside dosing. Clin Infect Dis. 30:2000;433-439
15. Guiliano R.A., Verpooten G.A., DeBroe M.E. The effect of dosing strategy on kidney cortical accumulation of aminoglycosides in rats. Am J Kidney Dis. 8:1986;292-296
16. Hatala R., Dinh T., Cook D.J. Once daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med. 124:1996;717-725
17. Freeman C.D., Nicolau D.P., Belliveau P.P., Nightingale C.H. Once daily aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother. 39:1997;677-686
18. Rybak M.J., Abate B.J., Kang S.L., et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 43:1999;1549-1555
19. Nicolau D.P., Freeman C.D., Belliveau P.P., et al. Experience with a once daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 39:1995;650-655
20. CDC. Recommendations for preventing the spread of vancomycin resistance. MMWR Morb Mortal Wkly Rep. 44:(RR-12):1994;1-13
21. Sowinski K.M., Mueller B.A., Grabe D.W., et al. Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. Am J Kidney Dis. 37:2001;766-776
22. Fogel M.A., Nussbaum P.B., Feintzeig I.D., et al. Cefazolin in chronic hemodialysis patients: a safe, effective alternative to vancomycin. Am J Kidney Dis. 32:1998;401-409
23. Kuypers D., Vanwalleghem J., Maes B., et al. Cefazolin serum concentrations with fixed intravenous dosing in patients on chronic hemodialysis treatment. Nephrol Dial Transplant. 14:1999;2050-2051
24. Geraci J.E., Hermans P.E. Vancomycin. Mayo Clin Proc. 58:1983;88-91
25. Ackerman B.H., Vannier A.M., Eudy E.B. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother. 36:1992;1766-1769
26. Freeman C.D., Quintiliani R., Nightingale C.H. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother. 27:1993;594-598
27. Saunders N.J. Vancomycin administration and monitoring reappraisal. J Antimicrob Chemother. 36:1995;279-282
28. Hammett-Stabler C.A., Johns T. Laboratory guidelines for monitoring of antimicrobial drugs. Clin Chem. 44:1998;1129-1140
29. Tobin C.M., Darville J.M., Thomson A.H., et al. Vancomycin therapeutic drug monitoring: is there a consensus view? J Antimicrob Chemother. 50:2002;713-718
30. Lacy M.K., Nicolau D.P., Nightingale C.H., Quintiliani R. The pharmacodynamics of aminoglycosides. Clin Infect Dis. 27:1998;23-27
31. Raveh D., Kopyt M., Hite Y., et al. Risk factors for nephrotoxicity in elderly patients receiving one-daily aminoglycosides. Q J Med. 95:2002;291-297
32. Golper T.A., Bennett W.M. Drug usage in dialysis patients. Nissenson R., Fine R.N., Gentile D.E. Clinical dialysis. 2nd edition:1990;608-630 Appleton and Lange, Norwalk (CT)
33. Vanholder R., DeSmet R., Glorieux G., et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 63:2003;1934-1943
34. Marx M.A., Frye R.F., Matzke G.R., Golper T.A. Cefazolin as empiric therapy in hemodialysis-related infections: efficacy and blood concentrations. Am J Kidney Dis. 32:1998;410-414
35. Sowinski K.M., Mueller B.A., Grabe D.W., et al. Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. Am J Kidney Dis. 37:2001;766-776
36. Barth R.H., DeVincenzo N., Zara A.C., Berlyne G.M. Vancomycin pharmacokinetics in high-flux hemodialysis. [abstract] J Am Soc Nephrol. 1:1990;348
37. Barth R.H., DeVincenzo N. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int. 50:1996;929-936
38. Foote E.F., Dreitlein W.B., Steward C.A., et al. Pharmacokinetics of vancomycin when administered during high flux hemodialysis. Clin Nephrol. 50:1998;51-55
39. Mason N.A., Neudeck B.L., Welage L.S., et al. Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers: post-dialysis versus intradialytic administration. Clin Nephrol. 60:2003;96-104
40. Maher J.F. Pharmacokinetics in patients with renal failure. Clin Nephrol. 21:1984;39-46
41. Maher J.F. Principles of dialysis and dialysis of drugs. Am J Med. 62:1977;475-481
42. Gibson T.P. Dialyzability of common therapeutic agents. Dial Transplant. 8:1979;24
43. Golper T.A., Wedel S.K., Kaplen A.A., et al. Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations. Intern Artif Organs. 8:1985;307-312
44. Golper T.A. Drug removal during continuous renal replacement therapy. Rose B.D. Uptodate. 2004;UpToDate, Wellesley (MA)
45. Vincent H.H., Vos M.C., Akcahuseyin E., et al. Drug clearance by continuous hemodialfiltration (CAVHD): analysis of sieving coefficients of diffusions. Blood Purif. 11:1993;99
46. Sigler M.H., Teehan B.P., Van Valkenbrugh D. Solute transport in continuous hemodialysis: a new treatment for acute renal failure. Kidney Int. 32:1987;562-571
47. Golper T.A. Update on drug sieving coefficients and dosing adjustments during continuous renal replacement therapies. Contrib Nephrol. 132:2001;349-353
48. Sewell D.L., Golper T.A., Brown S.D., et al. Stability of single and combination antimicrobial agents in various peritoneal dialysates in the presence of heparin and insulin. Am J Kidney Dis. 3:1983;209-212
49. Golper T.A. Drugs and peritoneal dialysis. Dial Transplant. 8:1979;41-43
50. Lasrich M., Maher J.M., Hirszel P., et al. Correlation of peritoneal transport rates with molecular weight: a method for predicting clearances. ASAIO J. 2:1979;107-113
51. Gross M., McDonald H.P. Effect of dialysate temperature and flow rate of peritoneal clearance. JAMA. 202:1967;363-366
52. Nolph K.D., Popovich R.P., Ghods A.J., et al. Determinants of low clearances of small solutes during peritoneal dialysis. Kidney Int. 13:1978;117-123
53. Manian F., Stone W., Alford R. Adverse antibiotic effects associated with renal insufficiency. Rev Infect Dis. 12:1990;236-249
54. Calandra G., Lydic E., Carrigan J., et al. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med. 84:1988;911-918
55. Ing T.S., Daugirdas J.T., Soung L.S., et al. Toxic effects of amantadine in patients with renal failure. Can Med Assoc J. 120:1979;695-698
56. Oldstone M.B.A., Nelson E. Central nervous system manifestations of penicillin toxicity in man. Neurology. 16:1966;693-700
57. Wright A.J. The penicillins. Mayo Clin Proc. 74:1999;290-307
58. Kroboth P.D., McNeil M.A., Kreeger A., et al. Hearing loss and erythromycin pharmacokinetics in a patient receiving hemodialysis. Arch Intern Med. 143:1983;1263-1265
59. Frankel M.C., Leslie B.R., Sax F.L., Soave R. Trimethoprim- sulfamethoxazole-related hypoglycemia in a patient with renal failure. N Y State J Med. 84:1984;30-31
60. Lawson D.H., Paice B.J. Adverse reactions to trimethoprim- sulfamethoxazole. Rev Infect Dis. 4:1982;429-433
61. Andrassy K., Scherz M., Ritz E., et al. Penicillin-induced coagulation disorder. Lancet. 2:1976;1039-1041
62. McClure P.D., Casserly J.G., Monsier C., et al. Carbenicillin-induced bleeding disorder. Lancet. 2:1970;1307-1308
63. Stuart J.J. Ticarcillin-induced hemorrhage in a patient with thrombocytosis. South Med J. 73:1980;1084-1085
64. 1 levels. Br J Haematol. 68:1988;63-66
65. Linden P.D., Sturkenboom M.C., Herings R.M., et al. Increases risk of Achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med. 163:2003;1801-1807
66. Smilack J.D. The tetracyclines. Mayo Clin Proc. 74:1999;727-729